Research indicates that up to 45% of dementia cases are linked to controllable conditions.2 This highlights the critical importance of early intervention and identification to reduce the long-term impact on the healthcare system and improve outcomes for millions of patients. The VeraBIND Tau test supports this effort by enabling early detection of active pathology in individuals who may not yet exhibit measurable cognitive decline or have not been diagnosed by their healthcare provider. Early diagnosis empowers patients and their caregivers to proactively address modifiable risk factors, manage metabolic contributors to disease, and better prepare for the potential onset of cognitive decline, ultimately improving care and reducing acute episodes.